“…Gs/Gi protein activation, however, will work through the stimulation/inhibition of adenylate cyclase, respectively, with subsequent up-or down-regulation of cyclic AMP (cAMP) production. Final effects of purinergic receptor-promoted signaling will depend on the cell type and other intra-/intercellular conditions, as i.e., in physiological embryonic and adult neurogenesis (Oliveira et al, 2016), and in various pathological scenarios, such as inflammatory (Beamer et al, 2016;Madeira et al, 2017;Przybyła et al, 2018), oncological (Allard et al, 2016;Vijayan et al, 2017;Whiteside, 2017;Kazemi et al, 2018), neurological (Burnstock et al, 2011;Stockwell et al, 2017), metabolic (Lindberg et al, 2015;Csóka et al, 2017;Parpura et al, 2017;Tozzi and Novak, 2017;Labazi et al, 2018), psychiatric (Cunha, 2008;Lindberg et al, 2015;Ortiz et al, 2015;Krügel, 2016;Cheffer et al, 2017;Oliveros et al, 2017), cognitive (Illes and Verkhratsky, 2016), and peripheral neuromuscular and/or neuromotor diseases (Robitaille, 1995;Kalmar, 2005;Burnstock et al, 2013;Jiménez et al, 2014;Bogacheva and Balezina, 2015;Puchałowicz et al, 2015;Safarzadeh et al, 2016).…”